volume 17, issue 2, P228-235 2018
DOI: 10.1016/j.jcf.2017.09.012
View full text
|
|
Share

Abstract: Compared with patients with higher lung function, respiratory events were more common in patients with ppFEV<40; aside from these events, the lumacaftor/ivacaftor safety profile was consistent with previous studies. Results suggest that patients with ppFEV<40 may benefit from treatment initiation at a lower dose with augmented monitoring before increasing to the full dose.

Search citation statements

Order By: Relevance

Citation Types

5
39
1

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals